Cambrex Revenue Growth Rates (CBM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cambrex Corp  (CBM)
 

CBM's Revenue Growth by Quarter and Year

Cambrex's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CBM Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December -
3rd Quarter September 148.56
2nd Quarter June 176.85
1st Quarter March 159.46
FY 484.87

CBMs Annual Revenue
Cambrex's Revenue in the fiscal year 2018 $ 532.09 millions
Cambrex's Revenue in the fiscal year 2017 $ 534.46 millions
Cambrex's Revenue in the fiscal year 2016 $ 490.64 millions
Cambrex's Revenue in the fiscal year 2015 $ 433.33 millions
Cambrex's Revenue in the fiscal year 2014 $ 374.61 millions




CBM Revenue third quarter 2019 Y/Y Growth Comment
Cambrex Corp achieved in the third quarter 2019, above Company average Revenue rise of 42% year on year, to $ 148.56 millions.

Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 86 other companies have achieved higher Revenue growth. While Cambrex Corp' s Revenue jump of 42% ranks overall at the positon no. 580 in the third quarter 2019.


CBM Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December - -26.31 % 2.48 % 13.88 %
3rd Quarter September 42 % -7.1 % 13.3 % 6.9 %
2nd Quarter June 16.31 % 13.01 % 13.41 % 11.25 %
1st Quarter March 13.01 % 34.37 % 10.84 % 22.2 %
FY   - -0.44 % 8.93 % -

Financial Statements
Cambrex's third quarter 2019 Revenue $ 148.56 millions CBM's Income Statement
Cambrex's third quarter 2018 Revenue $ 104.62 millions Quarterly CBM's Income Statement


CBM Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - 28.4 % 61.85 % 78.94 %
3rd Quarter September -15.99 % -31.19 % -16.3 % -16.22 %
2nd Quarter June 10.91 % 7.76 % 28.13 % 25.23 %
1st Quarter March 18.71 % -22.59 % -40.96 % -39.34 %
FY (Year on Year)   - -0.44 % 8.93 % -


Back to CBM Growth rate Comparisons >> Back to CBM Growth rate Comparisons >>


Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #169
Overall #580

Revenue Y/Y Growth Statistics
High Average Low
55.87 % 13.8 % -26.3 %
(Dec 31 2013)   (Dec 31 2018)
Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #169
Overall #580
Revenue Y/Y Growth Statistics
High Average Low
55.87 % 13.8 % -26.3 %
(Dec 31 2013)   (Dec 31 2018)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Cambrex's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
78.94 % 6.74 % -40.96 %
(Dec 31 2016)  


CBM's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2019 Cambrex Corp disclosed fall in Revenue from the second quarter by -15.99% to $ 148.56 millions, from $ 176.85 millions achived in the previous reporting period.

But that's not important problem, as Cambrex's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 225 other companies have achieved higher Revenue quarter on quarter growth. While Cambrex's Revenue growth quarter on quarter, overall rank is 4098.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #226
Healthcare Sector #575
Overall #4098
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #226
Healthcare Sector #575
Overall #4098
Revenue Q/Q Growth Statistics
High Average Low
78.94 % 6.74 % -40.96 %
(Dec 31 2016)  


CBM's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2019 Cambrex Corp disclosed fall in Revenue from the second quarter by -15.99% to $ 148.56 millions, from $ 176.85 millions achived in the previous reporting period.

But that's not important problem, as Cambrex's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 225 other companies have achieved higher Revenue quarter on quarter growth. While Cambrex's Revenue growth quarter on quarter, overall rank is 4098.


Cambrex's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)		 12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Sep 30 2018)
Cumulative Revenue 12 Months Ending $ 619.20 $ 575.26 $ 550.45 $ 532.09 $ 580.04
Y / Y Revenue Growth (TTM) 6.75 % -2.17 % -3.52 % -0.44 % 9.43 %
Year on Year Revenue Growth Overall Ranking # 1508 # 1402 # 0 # 2471 # 1499
Seqeuential Revenue Change (TTM) 7.64 % 4.51 % 3.45 % -8.27 % -1.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 2930 # 653 # 940 # 3453 # 941


Cumulative Revenue growth Comment
Although Cambrex's Annual Revenue growth year on year were below company's average 13.1% , Revenue announced in the Sep 30 2019 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6.75% year on year, from -2.17% in Jun 30 2019.

In the Healthcare sector 252 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1402 to 1508.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 156
Healthcare Sector # 253
Overall # 1508

Revenue TTM Y/Y Growth Statistics
High Average Low
35.12 %
 13.1 %
-3.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 156
Sector # 387
S&P 500 # 2930
Cumulative Revenue growth Comment
Although Cambrex's Annual Revenue growth year on year were below company's average 13.1% , Revenue announced in the Sep 30 2019 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6.75% year on year, from -2.17% in Jun 30 2019.

In the Healthcare sector 252 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1402 to 1508.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 156
Healthcare Sector # 253
Overall # 1508

Revenue TTM Y/Y Growth Statistics
High Average Low
35.12 %
13.1 %
-3.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 156
Sector # 387
S&P 500 # 2930




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CBM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2019
Akebia Therapeutics Inc 72.99%$ 72.990 millions
Dyadic International Inc 72.82%$ 72.816 millions
Kindred Biosciences Inc 72.50%$ 72.500 millions
Imac Holdings Inc 72.47%$ 72.470 millions
Luna Innovations Inc72.37%$ 72.368 millions
Agios Pharmaceuticals Inc 71.23%$ 71.233 millions
Adma Biologics Inc 70.73%$ 70.732 millions
Veru Inc 67.75%$ 67.748 millions
Accelerate Diagnostics Inc 67.60%$ 67.601 millions
10x Genomics Inc 67.20%$ 67.200 millions
Ocular Therapeutix Inc 66.47%$ 66.466 millions
Aspira Women s Health inc 66.02%$ 66.021 millions
Oncternal Therapeutics Inc 65.35%$ 65.350 millions
Clovis Oncology inc 65.24%$ 65.237 millions
Inotiv Inc 64.54%$ 64.545 millions
La Jolla Pharmaceutical Company64.44%$ 64.438 millions
Option Care Health Inc 62.72%$ 62.720 millions
Acadia Pharmaceuticals Inc 62.23%$ 62.226 millions
Clearpoint Neuro Inc 62.00%$ 62.003 millions
Vaxart Inc 61.57%$ 61.566 millions
Talphera Inc 61.27%$ 61.273 millions
Precision Optics Corporation Inc 61.27%$ 61.273 millions
Inspire Medical Systems inc 59.81%$ 59.813 millions
Caredx Inc 59.61%$ 59.606 millions
Semler Scientific inc 59.56%$ 59.563 millions
Reata Pharmaceuticals Inc 59.27%$ 59.266 millions
Chinook Therapeutics Inc 56.68%$ 56.676 millions
Sutro Biopharma Inc 56.67%$ 56.674 millions
Agenus Inc55.75%$ 55.752 millions
Aptevo Therapeutics Inc 54.72%$ 54.722 millions


About Cambrex Revenue Growth Rates (CBM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.